Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8145174 | 0.82 | ALDH1A1 (0.53) | KDM4EACHETTKPRKAG1PRKAA1 | |
| SCHEMBL28000408 | 0.81 | HTR1D (0.46) | KDM4EGLAGAAHTR1DPDE3B | |
| SCHEMBL27688753 | 0.79 | HTR1D (0.45) | KDM4EGLAGAAHTR1DPDE3B | |
| SCHEMBL3536445 | 0.78 | TTK (0.58) | KDM4ETTKMAPK8ALDH1A1MEN1 | |
| SCHEMBL29301505 | 0.78 | SLC2A1 (0.43) | HTR1DTTKMAPK8PRKAG1PRKAA1 | |
| SCHEMBL28000228 | 0.77 | PDE3B (0.44) | KDM4EGLAGAAHTR1DPDE3B | |
| SCHEMBL27945214 | 0.76 | HTR1D (0.42) | KDM4EGLAGAAHTR1DPDE3B | |
| SCHEMBL12515196 | 0.75 | KDM4E (0.46) | KDM4EGAAMAPK8POLBKMT2A | |
| SCHEMBL13548700 | 0.75 | KDR (0.56) | HTR1DTTKFGFR1KMT2A | |
| SCHEMBL16099536 | 0.75 | KDM4E (0.44) | KDM4EGAATTKMAPK8FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374025-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | Shenzhen Kangsu Pharmaceutical Technology Co., Ltd. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230374025-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | Shenzhen Kangsu Pharmaceutical Technology Co., Ltd. (CN) | 2023-11-23 | — | — | US | disclosed |
| EP-4261213-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | Shenzhen Kangsu Pharmaceutical Technology Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| US-20230192656-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192656-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4186894-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | Henan Medinno Pharmaceutical Technology Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192656-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | FGFR3, FGFR1, FGFR4 | KDM4E 1207/4885GLA 3704/4885GAA 1167/4885 |
| US-20230374025-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | FGFR3, FGFR1, FGFR4 | KDM4E 1207/4885GLA 3704/4885GAA 1167/4885 |
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | KDM4E 540/4885GLA 3724/4885GAA 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.